| |
Combining the industry-leading GPEx®️ cell line development with streamlined drug substance manufacturing. 
|
|
Today’s Big NewsDec 18, 2024 |
|
Just secured round from NVIDIA & Accel, Nebius is revolutionizing Life Sciences and Healthcare with powerful GPU Cloud. Cutting-edge AI/ML solutions, competitive pricing, and expert architectural support for breakthrough research. Learn more. 
|
|
| By James Waldron Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. |
|
|
|
By Gabrielle Masson Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and includes the possibility of up to $550 million biobucks. |
By Fraiser Kansteiner Under a new research collaboration unveiled Wednesday, Novo will pay Photys up to $186 million in upfront, development and commercial milestone payments to help develop proximity-based therapeutics for an unnamed cardiometabolic disease target. |
Sponsored by Inventus Discover how the Inventus Connect eSIM solutions, designed specifically for provisioned devices in clinical trials, are contributing to better patient outcomes with the only seamless global connectivity solution for eCOA. |
By Gabrielle Masson SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral nervous system instead of the central nervous system. |
Sponsored by NVIDIA Even though AI-designed drugs aren’t yet a household term for FDA-approved, commercially available therapies, they are a reality in clinical development pipelines. |
By James Waldron Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and it has now found a new home via a merger with fibrosis disease-focused Tvardi Therapeutics. |
By James Waldron The failure of Cognition Therapeutics’ Alzheimer’s disease candidate CT1812 in the SHINE trial earlier this year may have rubbed off some of the drug’s luster, but today’s win in the SHIMMER study should give the oral sigma-2 antagonist back its glow. |
By James Waldron The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has improved vision in a phase 1/2 trial for a type of eye disease, leading the company to set its sights on phase 3. |
By Kevin Dunleavy After the recent release of two independent studies from the University of Southern Denmark suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the Danish Medicines Agency has asked European officials to investigate. |
By Noah Tong The Value-Based Insurance Design model for Medicare Advantage plans will be terminated at the end of next year. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and what’s next for the GLP-1 drug class. |
|
|---|
|
|
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
